21 Jul 2026
nbsp
Fact.MR reports that the global DMD transcriptomic profiling market will expand from $816.8Mn in 2026 to $2.28Bn by 2036, a 10.8% CAGR. That represents an absolute dollar opportunity of $1.46Bn. RNA testing in Duchenne muscular dystrophy is now used to check whether a treatment has produced the intended change, with reports needing to show clearly whether the treatment affected the RNA linked to dystrophin production.
DMD treatment research now spans gene therapy, exon-skipping drugs, and anti-inflammatory approaches, all of which require RNA-based checks to show how the body responds. Single-cell and spatial RNA testing are gaining attention because they can study small muscle samples in greater detail and show differences between individual cells that standard RNA sequencing may miss, though safety monitoring has taken on greater weight following the FDA39s November 2025 boxed warning on Elevidys.
RNA sequencing leads technology demand at about 30%, giving a broad view of gene-expression changes and abnormal splicing across DMD samples, ahead of bulk and single-cell transcriptomics. Biomarker discovery tops application demand at roughly 30% as developers look for signals supporting patient selection and dose decisions, and skeletal muscle biopsy leads sample-type demand at close to 30% by giving the most direct view of dystrophin-related expression. Pharmaceutical and biotechnology companies place about 30% of end-user demand.
Germany leads at a 14.6% CAGR through 2036 on specialist muscle-disease research centres, with Brazil close behind at 13.5% on blood and cell-based testing alternatives to biopsy. The United States follows at 12.4% on new treatment approvals and biotechnology investment, ahead of South Korea (11.3%), the United Kingdom (10.3%), and Japan (9.2%).
Scarce and invasive skeletal muscle biopsy supply is the main brake, since repeat biopsy is difficult for patients and clinicians, and adoption slows where a test depends on tissue a site cannot collect consistently. Confounding biology adds a second constraint, as age and steroid exposure change the RNA background before therapy response can be measured, and fibrosis and inflammation add further noise laboratories must separate out.
Sarepta Therapeutics and Roche lead DMD therapy coverage, with Sarepta central to the commercial gene-therapy field through Elevidys and its associated safety checks. Illumina and Thermo Fisher Scientific provide the equipment and tools used for RNA sequencing and related testing, while Solid Biosciences and Regenxbio add newer gene-therapy programmes that keep muscle biopsy and biological testing central to clinical research.
Set clear limits for successful splice correction before choosing an RNA testing method for a study, and compare blood and cell-model results with muscle biopsy findings before treating them as easier alternatives. Record age, corticosteroid use, and muscle scarring when reviewing RNA results, and review standard RNA sequencing alongside single-cell and spatial methods before adding tests across several study sites.
Beyond the headline forecast, the Fact.MR study segments demand by technology, application, sample type, and end user. The study also compares country-level growth across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East amp Africa from 2026 to 2036. For related analysis, see Fact.MR39s coverage of RNA transcriptome profiling tests and cancer tumor profiling.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Duchenne Muscular Dystrophy Transcriptomic Profiling Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.